Perioperative PD-1 antibody tislelizumab plus chemotherapy for locally advanced gastro-oesophageal junction cancer: A prospective, nonrandomized, open-label, phase II trial

被引：0
|
作者：
Nie, Run-Cong
Ding, Ya
Yuan, Shu-Qiang
Li, Yuan-fang
Wang, Wei
Chen, Yongming
Cai, Muyan
Sun, Xiao-wei
Weng, Desheng
Li, Dandan
Zhao, Jingjing
Chen, Xiaojiang
Guan, Yuanxiang
Ma, Luo
Qiu, Haibo
Zhou, Zhi-wei
Zhang, Xiao-Shi
Chen, Ying-bo
机构：
[1] Sun Yat Sen Univ, Sun Yat sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Ctr Canc, Biotherapy Ctr, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[4] Sun Yat Sen Univ, Ctr Canc, Melanoma & Sarcoma Med Oncol Unit, Guangzhou, Peoples R China
[5] Sun Yat Sen Univ, Sun Ya Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Ctr Canc, Guangzhou, Peoples R China
[6] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Ctr Canc, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4083
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective phase II trial
    Yuan, Jing-Jing
    Ding, Jian-Wu
    Li, Jin-Wei
    Hu, Rong-Huan
    Gong, Dan
    Hu, Jia-Li
    Zhu, Kai-Bin
    Liu, Yan
    Ding, Yu-Hai
    Wei, Jia-Wang
    Zeng, Jian-Lun
    Lu, Zhi-Bing
    Yin, Wei-Hua
    Ai, Su-Fen
    Zha, Guo-Hua
    Zhang, Zhi-Lin
    Zou, Rui
    Zeng, Lei
    BMJ OPEN, 2022, 12 (08):
  • [42] An open-label, single arm, phase II trial of niraparib in combination with anti-PD1 antibody in recurrent/advanced stage endometrial cancer patients
    Li, J.
    Wei, W.
    ANNALS OF ONCOLOGY, 2021, 32 : S772 - S772
  • [43] Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial
    Herbst, Roy S.
    Arkenau, Hendrik-Tobias
    Santana-Davila, Rafael
    Calvo, Emiliano
    Paz-Ares, Luis
    Cassier, Philippe A.
    Bendell, Johanna
    Penel, Nicolas
    Krebs, Matthew G.
    Martin-Liberal, Juan
    Isambert, Nicolas
    Soriano, Andres
    Wermke, Martin
    Cultrera, Jennifer
    Gao, Ling
    Widau, Ryan C.
    Mi, Gu
    Jin, Jin
    Ferry, David
    Fuchs, Charles S.
    Petrylak, Daniel P.
    Chau, Ian
    LANCET ONCOLOGY, 2019, 20 (08): : 1109 - 1123
  • [44] Chemotherapy combined with cadonilimab (AK104) as neoadjuvant treatment for locally advanced gastric/gastro-oesophageal junction adenocarcinoma: study protocol for a single-arm, phase II clinical trial
    Zhang, Peng-Fei
    Zhang, Wei-Han
    Liu, Xi-Jiao
    He, Du
    Yang, Kun
    Gou, Hong-Feng
    Hu, Jian-Kun
    BMJ OPEN, 2024, 14 (12):
  • [45] Pan-cancer efficacy and safety of anlotinib plus PD-1 inhibitor in refractory solid tumor: A single-arm, open-label, phase II trial
    Qin, Bao-Dong
    Jiao, Xiao-Dong
    Wang, Zhan
    Liu, Ke
    Wu, Ying
    Ling, Yan
    Chen, Shi-Qi
    Zhong, Xue
    Duan, Xiao-Peng
    Qin, Wen-Xing
    Xue, Lei
    Guo, Zhen-Hong
    Zang, Yuan-Sheng
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (04) : 815 - 825
  • [46] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial
    Wei, W.
    Ban, X.
    Yang, F.
    Huang, Y.
    Li, J.
    Cheng, X.
    Zheng, M.
    Li, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S762 - S762
  • [47] Anlotinib plus tislelizumab combined with chemotherapy as neoadjuvant treatment in triple-negative breast cancer: A prospective, single-arm, open-label phase II study.
    Luo, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [48] Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF)
    Arkenau, Hendrik-Tobias
    Martin-Liberal, Juan
    Calvo, Emiliano
    Penel, Nicolas
    Krebs, Matthew G.
    Herbst, Roy S.
    Walgren, Richard A.
    Widau, Ryan C.
    Mi, Gu
    Jin, Jin
    Ferry, David
    Chau, Ian
    ONCOLOGIST, 2018, 23 (12): : 1407 - +
  • [49] Neoadjuvant XELOX chemotherapy with or without cadonilimab in locally advanced pMMR rectal cancer: Preliminary results from a randomized, open-label phase II trial
    Zhou, H.
    Gong, C.
    Zhang, J.
    Zou, S.
    Tang, J.
    Liang, J.
    Liu, Z.
    Zhang, W.
    Jiang, Z.
    Qu, W.
    Zhang, H.
    Zhao, Q.
    Sun, Y.
    Zhou, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S104 - S104
  • [50] Atezolizumab and trastuzumab plus chemotherapy in patients with HER2+locally advanced resectable gastric cancer or adenocarcinoma of the gastroesophageal junction: A multicenter, randomized, open-label phase II study.
    Peng, Zhi
    Zhang, Xiaotian
    Liang, Han
    Zheng, Zhichao
    Wang, Zhenning
    Liu, Hao
    Hu, Jiankun
    Sun, Yihong
    Zhang, Yanqiao
    Yan, Han
    Tong, Lin
    Xu, Jiahui
    Xie, Jessica
    Ji, Jiafu
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 312 - 312
12345